全球药物研发格局 - 中国公司在全球研发药物中占比20% 仅次于占比40%的美国 远高于5EU地区11%的占比 [1][2] - 中国药物研发管线占比接近5EU地区的两倍 反映出其在制药行业的强大作用 [1][2] 中国药物研发崛起的驱动因素 - 过去十年中国政府实施监管改革以提升全球竞争力 包括2015年推出的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》等政策 [3] - 对临床试验现代化的进一步关注 助力其实现成为药物研发主导区域的目标 [3] - 多年的监管举措使中国持续发展成为全球制药领域可信创新的关键来源 [4] 交易活动与行业合作 - 中国早期候选药物的涌现与中外药企许可协议激增同步 [4] - 今年最大交易之一是阿斯利康与石药集团达成的52亿美元慢性病候选药物研发协议 [4] - 中美生物制药公司之间的许可协议在去年创下历史新高 较2020年增长280% [5] - 大型药企交易总额从2023年的166亿美元增至2024年的415亿美元 增幅达66% 显示中国仍是发现研发管线的首选地 [6] 行业转型与未来展望 - 中国正持续从“模仿型”向全球创新者转型 重新定义全球药物研发格局 [6] - 其他市场需持续关注中国的研发管线资产以维持全球市场份额 [6]

Asia Crypto Regulations to Watch for in 2025. Photo by BeInCrypto Chainalysis’ 2025 APAC(Asia-Pacific) Crypto Adoption Report shows rapid growth in the region’s cryptocurrency activity. Monthly on-chain transaction values tripled, rising from about $81 billion in July 2022 to $244 billion in December 2024. India remains the largest market by transaction volume, supported by grassroots adoption, remittances, and fintech integration. Japan, while smaller in absolute volume, recorded the fastest year-on-y ...

Australia’s inability to close top M&A deals is becoming a growing frustration. The collapse of Abu Dhabi National Oil Company’s (ADNOC) $18.7 billion takeover bid for Santos (OTCPK: SSLZY) (the nation’s biggest supplier of natural gas) earlier this month is just the latest example. Valuation disputes, regulatory hurdles, and unexpected revelations are making Australia one of the most challenging places in the world to finalize big-ticket deals.“While the Consortium maintains a positive view of the Santos b ...

Putting your money into the market has long been part of your financial growth strategy. You’ve worked with financial advisors to create a diversified portfolio that aligns with your risk tolerance, and you make investment decisions based on years of experience. Learn More: Here’s Why Bitcoin Can Act Like ‘Digital Gold’ in Your Portfolio, Says Investing Expert Find Out: 3 Advanced Investing Moves Experts Use to Minimize Taxes and Help Boost Returns But you’re not a billionaire — at least not yet — and one ...